Lerodalcibep clinical trials
Also written LIB003 and HST101.
How each study uses lerodalcibep is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lerodalcibep studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 12 Dec 2025 · LEROCHOL · BLA 761427 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2021 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 0
LIB Therapeutics LLC (12) · Hasten Biopharmaceutical Co., Ltd. (2)
Related medicines
As reviewed, each with the page that says it.
- One of PCSK9 inhibitors source
Studies
Open first, then newest update. How each study uses lerodalcibep is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents With Familial HypercholesterolemiaNot yet recruitingPhase 3LIB Therapeutics LLCNCT07775339Written as Lerodalcibep
- Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FHEnrolling by invitationPhase 3LIB Therapeutics LLCNCT07102511Written as lerodalcibep 300 mg Monthly SC
- A Study on Evaluating the Safety of HST101 in Healthy Chinese ParticipantsEnrolling by invitationPhase 1Hasten Biopharmaceutical Co., Ltd.NCT06504043Written as HST101
- A Study on Efficacy and Safety of HST101 in Chinese Patients with HypercholesterolemiaRecruitingPhase 3Hasten Biopharmaceutical Co., Ltd.NCT06568471Written as Lerodalcibep
- Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C ReductionEnrolling by invitationPhase 3LIB Therapeutics LLCNCT04798430Written as lerodalcibep
- Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C ReductionCompletedPhase 3LIB Therapeutics LLCNCT04797104Written as lerodalcibep
- Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD PatientsCompletedPhase 3LIB Therapeutics LLCNCT05004675Written as lerodalcibep
- Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C ReductionActive, not recruitingPhase 3LIB Therapeutics LLCNCT04797247Written as lerodalcibep
- Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C ReductionActive, not recruitingPhase 3LIB Therapeutics LLCNCT04806893Written as lerodalcibep
- Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD PatientsCompletedPhase 3LIB Therapeutics LLCNCT04790513Written as lerodalcibep
- Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFHCompletedPhase 3LIB Therapeutics LLCNCT04034485Written as lerodalcibep
- Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug ProductCompletedPhase 3LIB Therapeutics LLCNCT05234775Written as lerodalcibep
- Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003CompletedPhase 2LIB Therapeutics LLCNCT03847974Written as LIB003
- Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C ReductionCompletedPhase 2LIB Therapeutics LLCNCT03549260Written as LIB003
Codes
What other systems call lerodalcibep · ClinicalTrials.gg INT002182
- MeSH (NLM) C000731963lerodalcibepOne source NLM
- UNII (FDA) 1PHP3QG5PZLERODALCIBEPConfirmed FDA, NLM
- NCI Thesaurus C175808LerodalcibepOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731963 | lerodalcibep | One source NLM |
| UNII (FDA) | 1PHP3QG5PZ | LERODALCIBEP | Confirmed FDA, NLM |
| NCI Thesaurus | C175808 | Lerodalcibep | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.